It turns out that CAR T cells can do more than directly attack cancer cells. They can be used as “micro-pharmacies” for precise therapeutic delivery in B-cell lymphomas.
Combining the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib may significantly improve progression-free survival in BRAF mutant melanoma, according to a new phase III trial.
Combining targeted radiation therapy with a neutrophil stimulant may enhance antitumor immunity, according to new research published in the Proceedings of the National Academy of Science of the United States of America.
Researchers in Texas are now reporting they have developed drug-loaded synthetic nanoparticles that can distinguish lung cancer cells from healthy cells.
The combination of dasatinib (Sprycel) and venetoclax (Venclexta) may have the potential to improve the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), according to Oregon researchers.
Investigators at the University of Colorado Cancer Center and Yale University are now reporting in the journal Cancer Cell on a new understanding of the cancer suppressing gene RhoDGI2 and how it may be involved in metastatic bladder cancer.
A new class of agents known as hypoxia-inducible factors-2 inhibitors may be more effective and better tolerated than sunitinib (Sutent), the current standard of care, in patients with renal cell carcinoma.
Researchers from the University of Virginia Cancer Center are now reporting that the experimental agent pevonedistat may be able to combat melanoma in whole new way.
Investigators think they may have found a strong predictor of which men with prostate cancer will develop resistance to androgen deprivation therapy.
A new study is suggesting that it may be possible to turn melanoma into a nonthreatening, easily curable disease.